Camidanlumab tesirine by ADC Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Camidanlumab tesirine overview

Camidanlumab tesirine is under development for the treatment of CD25-expressing relapsed/refractory Hodgkin lymphoma, relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms, Non-Hodgkin lymphoma. The therapeutic candidate is administered as an intravenous infusion. ADCT-301 is an antibody drug conjugate composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug–antibody ratio of 2.3. It was also under development for prostate cancer, relapsed or refractory CD25-positive acute lymphocytic leukemia (ALL). It was under devlopment for the treatment of advanced solid tumors including head and neck squamous cell carcinoma, fallopian tube cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, pancreas cancer, bladder cancer, renal cell carcinoma, melanoma, triple-negative breast cancer, ovarian cancer and colorectal cancer

ADC Therapeutics overview

ADC Therapeutics is a biotechnology company that develops antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors. It offers Zynlonta, a CD-19-directed antibody for treatment of e B-cell lymphoma in adult patients. The company is provides Loncastuximab Tesirine (Lonca)and Camidanlumab Tesirine (Cami). ADC Therapeutics develops ADCT-602 drug for B-cell acute lymphoblastic leukemia, ADCT-601 targeting AXL in solid tumors, ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer and myeloid leukemia. The company has operations in London, the UK and New Providence, and San Mateo, the US. ADC Therapeutics is headquartered in Lausanne, Switzerland.

For a complete picture of Camidanlumab tesirine’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.